Temprian Oncology

Temprian Oncology is a private, preclinical biotech founded in 2021 and based in San Diego, with research roots at Northwestern University. The company is advancing a novel nanoparticle prodrug platform, termed 'Supercarriers,' which targets metastatic melanoma by releasing an active drug specifically within the acidic pigment organelles of tumor cells. This approach seeks to improve efficacy and reduce side effects, positioning it as a potential successor or complement to current tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs). The company is pre-revenue, with a patent pending on its core technology.

Nanoparticle-based 'Supercarrier' prodrug platform that delivers a cytotoxic payload activated by the low pH specific to melanosomes (pigment organelles) within melanoma cells.

The metastatic melanoma market is dominated by large pharma with approved TKIs and ICIs, and is crowded with next-generation therapies in development. Temprian's niche is a highly targeted nanoparticle approach, but it must compete against numerous other targeted delivery and novel mechanism platforms also seeking to improve on current standards of care.